Share Facebook


Simponi

Contents


Simponi

Simponi (Golimumab) is a Tumor Necrosis Factor (TNF) blocker given by injection. It is prescribed for Ankylosing Spondylitis, Rheumatoid Arthritis (RA), and Psoriatic Arthritis.

Simponi is an antibody that binds to TNF - alpha (TNF-α), a major affector of the inflammatory response, and inhibits its activity.

In clinical trials Simponi showed decreased patient levels of C-Reactive Protein (CRP), Interleukin - 6 (IL-6), Intercellular Adhesion Molecule - 1 (ICAM-1), Matrix Metalloproteinase - 3 (MMP-3), and Vascular Endothelial Growth Factor (VEGF).

Simponi Risks and Side Effects

Risks of Simponi are similar to other TNF blocker medications and include:

Hypersensitivity Reaction (Allergic Reaction) to Simponi

In Patients with Congestive Heart Failure (CHF) Symptoms may Worsen

Patients are at Higher Risk for Cancer

Patients are at Higher Risk for Getting CNS Demyelinating Disorders or Symptoms of Pre-Existing Demyelinating Disorders May Worsen.
Examples of Demyelinating Disorders Include:
- Multiple Sclerosis (MS)
- Guillian Barre Syndrome
- Optic Neuritis
- Peripheral Demyelinating PolyNeuropathy

Increased Likelihood of Getting Severe Infection and Decreased Ability to Fight Infection

- Patients receiving TNF blocker therapy have a decreased ability to fight infection. As a result, TNF blocker therapy patients are at increased risk of getting an infection by an organism that might not usually cause an infection, called an opportunistic pathogen.

- Patients with an active infection or who have recently been exposed to persons with a contageous infection should not receive Simponi treatment until the infection (or risk of infection) has been cleared.

- Patients who have visited certain areas that are known to have or characteristically have certain infectious agents (or opportunistic microbes) should be cleared of the infectious organism before receiving Simponi treatment.

- Patients receiving TNF blocker treatments that have visited or live in certain areas are at higher risk of getting severe opportunistic infections. These areas include, Ohio, Mississippi River Valleys, and the Southwest United States. These areas have higher exposure to opportunistic invasive fungal pathogens, including Histoplasmosis (Histoplasma capsulatum)[2], Coccidioidomycosis (Valley Fever)[4], and Blastomycosis [5]. In some cases, patients and physicians were unaware of this increased risk and antifungal treatment was delayed, and were fatal. [3]

- Patients who have recently explored caves, or who enter caves as a profession, have higher rates of exposure to Histoplasmosis (inhalation of spores found in bat droppings). [2][3]

Johnson & Johnson Patient Assistance Foundation - Financial Help for Simponi

The Johnson & Johnson Patient Assistance Foundation, Inc. has generously provided medications to those who are in need of prescription medications taken at home or administered by a medical professional. Johnson & Johnson Patient Assistance Foundation offers financial assistance with Simponi
(Golimumab) prescriptions.

93% of Applicants are accepted into the Johnson & Johnson Patient Assistance Foundation Program.

Eligibility Guidelines (from Johnson & Johnson Patient Assistance Foundation, Inc. 2012)[6]:

1. Do not have public or private prescription drug coverage

2. Have a yearly gross income of:
-For Self-Administered Products
$21,660 or less for a single person
$29,140 or less for a family size of two*

-For Physician-Administered Products
$43,320 or less for a single person
$58,280 or less for a family size of two*
*Larger family sizes are adjusted accordingly

3.Reside in the United States or a United States territory

4.Are being treated by a U.S.-licensed healthcare provider

5.Are being treated as an outpatient

For more information regarding the Johnson & Johnson Patient Assistance Foundation to help with your prescription medications, please visit the Johnson & Johnson Patient Assistance Foundation website, Call 1 -800-652 - 6227 or click HERE.

References

1. Simponi (golimumab). http://www.simponi.com/hcp/sites/def...nformation.pdf

2. Histoplasmosis. Centers for Disease Control and Prevention. National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) Division of Foodbourne, Waterbourne, and Environmental Diseases (DFWED). http://www.cdc.gov/fungal/histoplasmosis

3. Risk Evaluation Strategy for Remicade. Federal Drug Administration (FDA).
http://www.fda.gov/downloads/Drugs/D.../UCM193310.pdf

4. Coccidioidomycosis (Valley Fever). Centers for Disease Control and Prevention. National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) Division of Foodbourne, Waterbourne, and Environmental Diseases (DFWED). http://www.cdc.gov/fungal/coccidioidomycosis

5. Blastomycosis. Centers for Disease Control and Prevention. National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) Division of Foodbourne, Waterbourne, and Environmental Diseases (DFWED). http://www.cdc.gov/fungal/blastomycosis

6. Johnson & Johnson Patient Assistance Foundation, Inc. Program for Prescription Financial Assistance. http://www.jjpaf.org/how-we-help/index.html

Popular Threads Discussing Simponi



Page Tools
No one has commented on this article.

Reply
Page Tools
Search this Page


All times are GMT -5. The time now is 03:17 AM.
Copyright 2006-2017 Crohnsforum.com